Notice: Private records are filtered that would not be displayed.
Sort:
  • PROJ Pancreatic ductal adenocarcinoma adjuvant chemotherapy vulnerability: a prospective observational study

    Chenxu Gao, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital,2023.04.11

    Description

    We report a prospective observational study enrolled 1,171 PDAC patients who had pancreatectomy. After substantive follow-up and proteomic profiling of 191 patient samples (referred to as 'PDAC_Proteomics'), we identified functional modules with clinical relevance, established a proteomic-level prognostic risk model for PDAC, and cross-validated the LASSO model using external as well as independent in-house cohorts. The 14 proteins in the established model were individually and independently quantified for each of 50 PDAC patients using parallel-reaction monitoring (PRM; see 'PDAC_PRM'). In addition, 185 out of 191 PDACs were subjected to RNA isolation after the dissection of formalin-fixed paraffin-embedding (FFPE) tumor tissues, followed by transcriptomic RNA-seq (see 'PDAC_Transcriptomic').

    OEP004100

  • PROJ glomus jugulare tumors

    maoxiang xu, shanghai jiaotong university,2022.06.09

    Description

    OEP003436

  • PROJ PDAC-NatureMedicine-test

    Chenxu Gao, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital,2023.04.11

    Description

    OEP004098

  • PROJ Pancreatic ductal adenocarcinoma adjuvant chemotherapy vulnerability: a prospective observational study

    Chenxu Gao, Shanghai Jiao Tong University Medical School Affiliated Ruijin Hospital,2023.03.26

    Description

    A prospective observational study enrolled 1,171 PDAC patients who had pancreatectomy is reported. After substantive follow-up and proteomic profiling of 191 patient samples, we identify functional modules with clinical relevance, establish a proteomic-level prognostic risk model for PDAC, and cross-validate the model using external as well as independent in-house cohorts. Two new biomarkers, indicative of PDAC adjuvant chemotherapy sensitivity, are discovered using integrated analysis of both clinical and proteomic datasets. Our prospective evidence points us towards a subgroup of patients to whom mild adjuvant chemo plan (for example S-1) might provide overall survival benefit.

    OEP004079

  • PROJ MT-Enviro

    Yu Zhang, Shanghai Jiaotong University,2023.02.23

    Description

    The mock communities of MT-Enviro are expected to improve standardization and quality assurance of metatranscriptomic analysis for environmental microbes.

    OEP003879

  • PROJ Bacteriophage contributes folate-associated cofactors to microbial consortia implied by ultrabasic viruses in steel slag leachate

    Yu He, China University of Geosciences (Wuhan),2023.07.19

    Description

    Viral communities in steel slag leachate

    OEP004270

  • PROJ cfDNA-seq of pregnancy women

    Bowei Han, Southern Medical University,2019.09.20

    Description

    To develop a noninvasive in vivo monitoring platform of the physiology and pathology of pregnancy, we merged whole-genome cfDNA sequencing data generated from non-invasive prenatal testing (NIPT), all the data is in aligned BAM format.

    OEP000486

  • PROJ EMSY enhances cancer stem cell self-renewal and tumorigenesis by reshaping methionine metabolism in triple-negative breast cancer

    Cui-Cui Liu, ,2023.11.20

    Description

    Treatment of triple-negative breast cancer (TNBC) remains challenging. Cancer stem cells (CSCs) are the most intractable subpopulation of TNBC cells, which has associated with a high risk of relapse and poor prognosis. However, eradication of CSCs continues to be difficult. Here, we integrated the multiomics data of our large TNBC cohort (n=360) to identify vital markers of CSCs. We discovered that EMSY, inducing a BRCAness phenotype, was preferentially expressed in breast CSCs, promoted the enrichment of ALDH+ cells and was positively correlated with poor relapse-free survival. Mechanistically, EMSY competitively bound to the Jmjc domain, which was critical for the enzyme activity of the KDM5B-specific H3K4 demethylase to reshape methionine metabolism and promote CSC self-renewal and tumorigenesis in an H3K4 methylation-dependent manner. Moreover, EMSY accumulation in TNBC cells sensitized them to PARP inhibitors against bulk cells and methionine deprivation against CSCs. These findings indicate that clinically relevant eradication of CSCs could be achieved with a strategy that targets CSC-specific vulnerabilities in amino acid metabolism.

    OEP004750

  • PROJ KRAS-G12V mRNA Vaccine and Pembrolizumab in Advanced Solid Tumors: Case report

    Xinjing Wang, Department of General Surgery, Pancreatic Disease Center,2023.11.19

    Description

    Here, we report two patients of advanced solid tumor both of whom achieved partial response after treated with combination therapy using an mRNA vaccine targeting KRAS G12V mutation and Pembrolizumab. Both patients were HLA-A11:01 subtype and their tumor harbors KRAS G12V mutation. Consistent with the clinical findings, both patients had a significant expansion of polyfunctional, KRAS G12V-specific CD8 cytotoxic T cells with high levels of INF-γ and TNF-α upon neoantigen stimulation.

    OEP004748

  • PROJ 20231117_rawdata

    GuLan chun, Fujun,2023.11.17

    Description

    OEP004747